Amgen AMGN and Novo Nordisk NVO are among the largest companies in the pharmaceutical space. Amgen boasts one of the largest ...

Novo Nordisk did not immediately respond Pharmaceutical Technology’s request for comment. The request to the FDA is just the latest action Novo Nordisk has taken related to semaglutide compounding.

The Novo Nordisk/Ascendis partnership’s lead program is once-monthly injectable semaglutide for type 2 diabetes and obesity. This product candidate will be developed with Ascendis Pharma ...

Novo Nordisk reups bid for high-dose Ozempic after March FDA snub It's crucial to help patients living with obesity understand that "it's not their fault, and that it's not just about eating less ...

The weight endpoint is a clear win for tirzepatide over 1 mg of semaglutide. However, Novo recently linked once-weekly dosing with 2.4 mg of semaglutide to a 14.9% reduction in body weight by Week 68.

Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of its next-generation obesity drug candidate CagriSema did not reach the ...

Novo Nordisk and Eli Lilly are locked in a tough fight, both vying for the top spot in the GLP-1 diabetes treatment class. On strategy they’ve both pursued is increasing the dosing of their ...

Bagsværd, Denmark, 20 December 2024 – Novo Nordisk today announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE programme. REDEFINE 1 is a 68-week efficacy and ...

Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, and stay competitive. Learn more on NVO stock here.

Novo Nordisk said the data on 10 deaths and more than 100 hospitalizations came from the US Food and Drug Administration’s adverse event reporting database for semaglutide; the FDA warns that ...